EA200970353A1 - COMBINED MEDICINE - Google Patents

COMBINED MEDICINE

Info

Publication number
EA200970353A1
EA200970353A1 EA200970353A EA200970353A EA200970353A1 EA 200970353 A1 EA200970353 A1 EA 200970353A1 EA 200970353 A EA200970353 A EA 200970353A EA 200970353 A EA200970353 A EA 200970353A EA 200970353 A1 EA200970353 A1 EA 200970353A1
Authority
EA
Eurasian Patent Office
Prior art keywords
agent
combined medicine
combination
provides
present
Prior art date
Application number
EA200970353A
Other languages
Russian (ru)
Inventor
Йосиказу Охта
Тосия Тамура
Синдзи Такаги
Original Assignee
Такеда Фармасьютикал Компани Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Такеда Фармасьютикал Компани Лимитед filed Critical Такеда Фармасьютикал Компани Лимитед
Publication of EA200970353A1 publication Critical patent/EA200970353A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

Настоящее изобретение предоставляет фармацевтическое средство, содержащее ингибитор HER2 и гормональное терапевтическое средство или противораковое средство в комбинации. Настоящее изобретение предоставляет фармацевтическое средство, содержащее (1) ингибитор HER2, имеющий структуру пирролопиримидина или структуру пиразолопиримидина, и (2) гормональное терапевтическое средство или противораковое средство в комбинации.The present invention provides a pharmaceutical agent comprising an HER2 inhibitor and a hormonal therapeutic agent or anti-cancer agent in combination. The present invention provides a pharmaceutical agent comprising (1) an HER2 inhibitor having a pyrrolopyrimidine structure or a pyrazolopyrimidine structure, and (2) a hormonal therapeutic agent or anti-cancer agent in combination.

EA200970353A 2006-10-06 2007-10-05 COMBINED MEDICINE EA200970353A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2006275841 2006-10-06
JP2007057902 2007-03-07
PCT/JP2007/070026 WO2008044782A2 (en) 2006-10-06 2007-10-05 Combination drug

Publications (1)

Publication Number Publication Date
EA200970353A1 true EA200970353A1 (en) 2009-10-30

Family

ID=39283276

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200970353A EA200970353A1 (en) 2006-10-06 2007-10-05 COMBINED MEDICINE

Country Status (23)

Country Link
US (1) US20100008912A1 (en)
EP (2) EP2063895A2 (en)
JP (1) JP2010505745A (en)
KR (1) KR20090094804A (en)
CN (1) CN101553222A (en)
AR (1) AR063152A1 (en)
AU (1) AU2007307489A1 (en)
BR (1) BRPI0717477A2 (en)
CA (1) CA2665692A1 (en)
CL (1) CL2007002878A1 (en)
CO (1) CO6180429A2 (en)
CR (1) CR10759A (en)
EA (1) EA200970353A1 (en)
EC (1) ECSP099311A (en)
GE (1) GEP20115218B (en)
IL (1) IL197883A0 (en)
MA (1) MA30815B1 (en)
MX (1) MX2009003660A (en)
NO (1) NO20091628L (en)
PE (1) PE20080977A1 (en)
TN (1) TN2009000119A1 (en)
TW (1) TW200823218A (en)
WO (1) WO2008044782A2 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2569016C (en) * 2004-06-02 2012-11-27 Takeda Pharmaceutical Company Limited Fused heterocyclic compound
CA2691251A1 (en) 2007-06-19 2008-12-24 Yoshikazu Ohta Preventive/remedy for cancer
US8946239B2 (en) 2008-07-10 2015-02-03 Duquesne University Of The Holy Spirit Substituted pyrrolo, -furano, and cyclopentylpyrimidines having antimitotic and/or antitumor activity and methods of use thereof
WO2011040212A1 (en) 2009-10-01 2011-04-07 Takeda Pharmaceutical Company Limited Therapeutic agent for brain tumor
KR101592258B1 (en) * 2014-06-20 2016-02-05 보령제약 주식회사 formulation and method of preparing the same
US10317014B2 (en) * 2016-08-09 2019-06-11 Baker Hughes, A Ge Company, Llc Flow variation system
EP4121130A4 (en) * 2020-03-17 2024-03-27 Microvention Inc Liquid embolics

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
YU33730B (en) * 1967-04-18 1978-02-28 Farmaceutici Italia Process for preparing a novel antibiotic substance and salts thereof
JPS6019790A (en) * 1983-07-14 1985-01-31 Yakult Honsha Co Ltd Novel camptothecin derivative
FR2601675B1 (en) * 1986-07-17 1988-09-23 Rhone Poulenc Sante TAXOL DERIVATIVES, THEIR PREPARATION AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
WO1989006692A1 (en) * 1988-01-12 1989-07-27 Genentech, Inc. Method of treating tumor cells by inhibiting growth factor receptor function
US6136846A (en) * 1999-10-25 2000-10-24 Supergen, Inc. Formulation for paclitaxel
AU2003265901B2 (en) * 2002-09-04 2006-09-14 Pharmacopeia, Inc. Pyrazolopyrimidines as cyclin dependent kinase inhibitors
JP4366683B2 (en) 2003-07-28 2009-11-18 武原 力 Thermosyphon
CA2569016C (en) * 2004-06-02 2012-11-27 Takeda Pharmaceutical Company Limited Fused heterocyclic compound
WO2005120512A2 (en) 2004-06-04 2005-12-22 Smithkline Beecham (Cork) Limited Cancer treatment method
CA2578384A1 (en) * 2004-09-06 2006-03-16 Altana Pharma Ag Novel pyrazolopyrimidines
JP2006275841A (en) 2005-03-30 2006-10-12 Taiheiyo Cement Corp Method for quantitating amount of diethylene glycol in cement
JP2007057902A (en) 2005-08-25 2007-03-08 Seiko Epson Corp Image forming apparatus

Also Published As

Publication number Publication date
CN101553222A (en) 2009-10-07
BRPI0717477A2 (en) 2015-06-16
AU2007307489A1 (en) 2008-04-17
EP2063895A2 (en) 2009-06-03
CO6180429A2 (en) 2010-07-19
MX2009003660A (en) 2009-04-22
PE20080977A1 (en) 2008-09-05
WO2008044782A3 (en) 2008-12-11
ECSP099311A (en) 2009-06-30
EP2359825A2 (en) 2011-08-24
TN2009000119A1 (en) 2010-10-18
WO2008044782A2 (en) 2008-04-17
IL197883A0 (en) 2009-12-24
GEP20115218B (en) 2011-05-25
NO20091628L (en) 2009-06-26
US20100008912A1 (en) 2010-01-14
TW200823218A (en) 2008-06-01
MA30815B1 (en) 2009-10-01
CR10759A (en) 2009-05-27
AR063152A1 (en) 2008-12-30
KR20090094804A (en) 2009-09-08
CA2665692A1 (en) 2008-04-17
CL2007002878A1 (en) 2008-08-01
JP2010505745A (en) 2010-02-25

Similar Documents

Publication Publication Date Title
ECSP077238A (en) COMPOSITIONS FOR DELIVERY OF HIGHLY SOLUBLE DRUGS IN WATER
EA200802184A1 (en) PHARMACEUTICAL COMPOSITIONS WITH DPP IV INHIBITORS
UA94734C2 (en) THERAPEUTIC ANTIBODIY WHICH BINDS TO b-AMYLOID PEPTIDE
EA200970353A1 (en) COMBINED MEDICINE
WO2007101224A3 (en) Inhibitors of the unfolded protein response and methods for their use
IL184051A (en) Acylated glp-1 compounds, pharmaceutical compositions comprising them and their use in the manufacture of medicaments
EA200602047A1 (en) SULPHONYLETHYL PHOSPHORODYAMIDATES, INTENDED FOR USE IN CANCER TREATMENT
CY1109537T1 (en) Peptides and Peptide Derivatives, PREPARATION OF THESE ALSO USE THESE FOR THE PREPARATION OF THERAPEUTIC AND / OR PREVENTIVE ACTIVE ACTION
LU92202I9 (en)
TW200730190A (en) New combination to treat liver fibrosis
DK1869185T3 (en) Conjugate with P21 protein for cancer treatment
PT1713438E (en) Medicinal soap
MXPA05008572A (en) Use of dipyridamole in combination with acetylsalicylic acid and an angiotensin ii antagonist for stroke prevention.
TW200942544A (en) Combination drug
GEP20104911B (en) Medicinal agent for preventing progression of apoptotic and jugulating necrotic changes in the organism tissues
DOP2009000066A (en) COMBINED PHARMACO
WO2007012967A3 (en) Combination of voriconazole and fluconazole
BRPI0407574A (en) pharmaceutical combinations comprising a nos inhibitor and an nmda receptor antagonist
DK1962822T3 (en) Therapy of malignant neoplasias
SG153877A1 (en) Treatment of cancer
CL2004000633A1 (en) COPOLYMER COMPOUNDS, PHARMACEUTICAL COMPOSITION THAT CONTAINS THEM AND PREPARATION PROCEDURE, USEFUL IN THE TREATMENT OF OSEAS METABOLIC DISEASES.
AR055352A1 (en) PHARMACEUTICAL COMPOSITION
TNSN06454A1 (en) Treatment of cancer
BRPI0506066A (en) composition for atherosclerotic disease
CL2007003028A1 (en) COMPOUNDS DERIVED FROM BICYCLE TRIAZOLS, PROTEIN CINASE MODULATORS; PREPARATION METHOD; PHARMACEUTICAL COMPOSITION; AND USE IN THE TREATMENT OF CANCER.